 Anti-Asthmatic Agents
"Anti-Asthmatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat asthma.
| Descriptor ID |
D018927
|
| MeSH Number(s) |
D27.505.954.796.050
|
| Concept/Terms |
Anti-Asthmatic Agents- Anti-Asthmatic Agents
- Agents, Anti-Asthmatic
- Anti Asthmatic Agents
- Anti-Asthmatics
- Anti Asthmatics
- Antiasthmatic Drugs
- Drugs, Antiasthmatic
- Antiasthmatics
- Anti-Asthmatic Drugs
- Anti Asthmatic Drugs
- Drugs, Anti-Asthmatic
- Antiasthmatic Agents
- Agents, Antiasthmatic
|
Below are MeSH descriptors whose meaning is more general than "Anti-Asthmatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Asthmatic Agents".
This graph shows the total number of publications written about "Anti-Asthmatic Agents" by people in this website by year, and whether "Anti-Asthmatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 | | 1997 | 4 | 0 | 4 | | 1998 | 4 | 0 | 4 | | 1999 | 4 | 1 | 5 | | 2000 | 3 | 0 | 3 | | 2001 | 2 | 0 | 2 | | 2002 | 7 | 0 | 7 | | 2003 | 9 | 1 | 10 | | 2004 | 5 | 3 | 8 | | 2005 | 5 | 5 | 10 | | 2006 | 7 | 3 | 10 | | 2007 | 5 | 1 | 6 | | 2008 | 7 | 7 | 14 | | 2009 | 4 | 4 | 8 | | 2010 | 5 | 4 | 9 | | 2011 | 7 | 5 | 12 | | 2012 | 2 | 6 | 8 | | 2013 | 6 | 2 | 8 | | 2014 | 3 | 2 | 5 | | 2015 | 10 | 3 | 13 | | 2016 | 8 | 8 | 16 | | 2017 | 11 | 4 | 15 | | 2018 | 13 | 5 | 18 | | 2019 | 8 | 0 | 8 | | 2020 | 15 | 3 | 18 | | 2021 | 11 | 1 | 12 | | 2022 | 10 | 0 | 10 | | 2023 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-Asthmatic Agents" by people in Profiles.
-
Chen W, Tran TN, Sadatsafavi M, Murray R, Wong NCB, Ali N, Ariti C, Bulathsinhala L, Gil EG, FitzGerald JM, Alacqua M, Al-Ahmad M, Altraja A, Al-Lehebi R, Bhutani M, Bjermer L, Bjerrum AS, Bourdin A, von B?low A, Busby J, Canonica GW, Carter V, Christoff GC, Cosio BG, Costello RW, Fonseca JA, Gibson PG, Yoo KH, Heaney LG, Heffler E, Hew M, Hilberg O, Hoyte F, Iwanaga T, Jackson DJ, Jones RC, Koh MS, Kuna P, Larenas-Linnemann D, Lehmann S, Lehtim?ki L, Lyu J, Mahboub B, Maspero J, Menzies-Gow AN, Newell A, Sirena C, Papadopoulos NG, Papaioannou AI, Perez-de-Llano L, Perng Steve DW, Peters M, Pfeffer PE, Porsbjerg CM, Popov TA, Rhee CK, Salvi S, Taill? C, Taube C, Torres-Duque CA, Ulrik C, Ra SW, Wang E, Wechsler ME, Price DB. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2023 09; 11(9):2732-2747.
-
Papadopoulos NG, Szefler SJ, Bacharier LB, Maspero JF, Domingo C, Fiocchi A, Lee JK, Daizadeh N, Lederer DJ, Hardin M, Gall R, Djandji M, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023 08; 78(8):2157-2167.
-
Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, Peters M, Christoff GC, Sadatsafavi M, Torres-Duque CA, Altraja A, Lehtim?ki L, Papadopoulos NG, Salvi S, Costello RW, Cushen B, Heffler E, Iwanaga T, Al-Ahmad M, Larenas-Linnemann D, Kuna P, Fonseca JA, Al-Lehebi R, Rhee CK, Perez-de-Llano L, Perng Steve DW, Mahboub B, Wang E, Goh C, Lyu J, Newell A, Alacqua M, Belevskiy AS, Bhutani M, Bjermer L, Bjornsdottir U, Bourdin A, Bulow AV, Busby J, Canonica GW, Cosio BG, Dorscheid DR, Mu?oz-Esquerre M, FitzGerald JM, Gil EG, Gibson PG, Heaney LG, Hew M, Hilberg O, Hoyte F, Jackson DJ, Koh MS, Ko HB, Lee JH, Lehmann S, Chaves Loureiro C, L??v?ksd?ttir D, Menzies-Gow AN, Mitchell P, Papaioannou AI, Popov TA, Porsbjerg CM, Salameh L, Sirena C, Taill? C, Taube C, Tohda Y, Wechsler ME, Price DB. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023 Jul; 78(7):1934-1948.
-
Bleecker ER, Meyers DA, Billheimer D, Li H, Newbold P, Kwiatek J, Hirsch I, Katial R, Li X. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. J Allergy Clin Immunol Pract. 2023 Jun; 11(6):1805-1813.
-
Anderson WC, Banzon TM, Chawes B, Papadopoulos NG, Phipatanakul W, Szefler SJ. Factors to Consider in Prescribing Asthma Biologic Therapies to Children. J Allergy Clin Immunol Pract. 2023 03; 11(3):693-701.
-
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2023 03; 11(3):885-895.e13.
-
Stempel DA, Szefler SJ. Adding a Biologic to Asthma Therapy: The Role of Adherence in Selecting the Right Patient. J Allergy Clin Immunol Pract. 2022 11; 10(11):2949-2950.
-
Bender B, Oppenheimer J, George M, Brown R, Patel A, Hill T, Boe A, Mayen Herrera E, Dotiwala Z, Casciano J, Bernstein JA. Assessment of Real-World Escalation to Biologics in US Patients With Asthma. J Allergy Clin Immunol Pract. 2022 11; 10(11):2941-2948.
-
May KR, Oppenheimer JJ, Szefler SJ. Over-the-Counter Availability of Rescue Inhalers for Asthma. JAMA. 2022 07 12; 328(2):215.
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab". Adv Ther. 2022 08; 39(8):3862-3865.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|